We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.25%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.01B
AUM Growth
+$52.2M
Cap. Flow
+$30.7M
Cap. Flow %
3.04%
Top 10 Hldgs %
32.72%
Holding
140
New
6
Increased
28
Reduced
47
Closed
15

Top Buys

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$17.7M
2
HUM icon
Humana
HUM
+$13.6M
3
KTWO
K2M Group Holdings, Inc
KTWO
+$13.2M
4
FIT
Fitbit, Inc. Class A common stock
FIT
+$12.2M
5
ESPR
Esperion Therapeutics
ESPR
+$12.1M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$20.4M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.6M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.4M
4
THC icon
Tenet Healthcare
THC
+$9.34M
5
ONC
BeOne Medicines Ltd
ONC
+$8.53M

Sector Composition

Rank Sector Weight
1 Healthcare 95.24%
2 Industrials 0.39%
3 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGN icon
1
Align Technology
ALGN
$12.7B
$40.5M 4.02%
161,388
-12,208
-7% -$3.14M
ELV icon
2
Elevance Health
ELV
$80.9B
$39.8M 3.94%
181,243
– –
CELG
3
DELISTED
Celgene Corp
CELG
$38.8M 3.84%
434,400
+30,135
+7% +$2.89M
ISRG icon
4
Intuitive Surgical
ISRG
$122B
$34.1M 3.38%
247,770
-40,623
-14% -$5.67M
ABT icon
5
Abbott
ABT
$175B
$33.9M 3.35%
565,000
+35,000
+7% +$2.11M
UNH icon
6
UnitedHealth
UNH
$387B
$30.5M 3.02%
142,590
-320
-0.2% -$73.1K
ILMN icon
7
Illumina
ILMN
$28.2B
$30.1M 2.98%
130,837
-23,232
-15% -$5.32M
MDT icon
8
Medtronic
MDT
$106B
$28.6M 2.84%
357,000
+140,000
+65% +$11.5M
EW icon
9
Edwards Lifesciences
EW
$49.4B
$27.5M 2.73%
591,480
+26,880
+5% +$1.17M
DXCM icon
10
DexCom
DXCM
$29.6B
$26.4M 2.62%
1,425,560
+358,600
+34% +$5.3M
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.5B
$22.9M 2.27%
151,722
-3,860
-2% -$566K
HUM icon
12
Humana
HUM
$48B
$22.5M 2.23%
83,700
+50,350
+151% +$13.6M
TDOC icon
13
Teladoc Health
TDOC
$1.7B
$20.8M 2.06%
515,694
+468,694
+997% +$17.7M
DHR icon
14
Danaher
DHR
$144B
$19.8M 1.96%
227,856
– –
INCY icon
15
Incyte
INCY
$23.4B
$19.2M 1.9%
230,626
-950
-0.4% -$85.7K
BSX icon
16
Boston Scientific
BSX
$65.4B
$19M 1.88%
696,000
– –
COR icon
17
Cencora
COR
$59.9B
$18.6M 1.84%
215,178
+4,237
+2% +$407K
SYK icon
18
Stryker
SYK
$123B
$18.2M 1.81%
113,300
+22,000
+24% +$3.55M
HOLX
19
DELISTED
Hologic
HOLX
$18.1M 1.79%
483,894
– –
WBA
20
DELISTED
Walgreens Boots Alliance
WBA
$17.3M 1.71%
263,560
-33,000
-11% -$2.36M
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$123B
$15.8M 1.56%
96,810
+600
+0.6% +$98K
ALXN
22
DELISTED
Alexion Pharmaceuticals
ALXN
$14.6M 1.45%
131,390
+620
+0.5% +$74.1K
MGNX icon
23
MacroGenics
MGNX
$285M
$14.2M 1.4%
563,151
-1,250
-0.2% -$30.4K
BAX icon
24
Baxter International
BAX
$11.7B
$14M 1.39%
216,000
– –
IONS icon
25
Ionis Pharmaceuticals
IONS
$8.99B
$13.8M 1.36%
312,186
+55,480
+22% +$2.82M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2018 Portfolio in Review

As of Q1 2018, Bellevue Group held 140 positions worth $1.01B, up 5.4% from $957M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $30.7M of net new capital in Q1 2018, opening 6 new positions and adding to 28 existing holdings. Its largest new stake was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $11.4M trimmed.

  • Bellevue Group's largest Q1 2018 buy was K2M Group Holdings, Inc: 667,941 shares worth $12.7M.
  • Bellevue Group added most to Teladoc Health in Q1 2018, an estimated $17.7M increase.
  • Bellevue Group's biggest Q1 2018 reduction was Teva Pharmaceuticals, cutting an estimated $11.4M.
  • Bellevue Group fully exited Eli Lilly in Q1 2018, selling an estimated $20.4M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.01B portfolio in Q1 2018.
  • Bellevue Group opened 6 new positions and closed 15 in Q1 2018.
  • Bellevue Group's portfolio value rose 5.4% quarter-over-quarter to $1.01B.

Based on Bellevue Group's 13F filing for Q1 2018, filed 9 May 2018.